Fetal Growth Retardation
|
0.900 |
Biomarker
|
phenotype |
CTD_human |
Here we show that deletion from the Igf2 gene of a transcript (P0) specifically expressed in the labyrinthine trophoblast of the placenta leads to reduced growth of the placenta, followed several days later by fetal growth restriction.
|
12087403 |
2002 |
Fetal Growth Retardation
|
0.900 |
AlteredExpression
|
phenotype |
BEFREE |
The increase in the transcription of IGF2 and IGF1R in IUGR term placentas may represent a counter regulatory mechanism in response to the growth retardation.
|
9491374 |
1998 |
Fetal Growth Retardation
|
0.900 |
Biomarker
|
phenotype |
RGD |
Decreased IGF-II expression in placenta also may contribute to decreased placental growth and, in turn, to IUGR.(ABSTRACT TRUNCATED AT 250 WORDS)
|
1408464 |
1992 |
Fetal Growth Retardation
|
0.900 |
Biomarker
|
phenotype |
HPO |
|
|
|
Russell-Silver syndrome
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, while both IGF2 mutations and H19/IGF2:IG-DMR epimutations lead to SRS, a certain degree of phenotypic difference is observed between the two groups, probably due to the different IGF2 expression pattern in target tissues.
|
31544945 |
2020 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of 91H promotes tumour growth and metastasis, and is associated with a poor prognosis of HCC at least partially by positively regulating the expression of IGF2 through bivalent histone modification changes characterized by H3K4me3 and H3K27me3 at the P3 and P4 promoters.
|
31724285 |
2020 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The unmethylation rate of IGF-II P3 CpG sites was 100% in the HCC-, 52.5% in the paracancerous-, and none (0%) in the distal noncancerous-tissues.
|
30692043 |
2019 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Human insulin-like growth factor (IGF) axis affects the molecular pathogenesis of hepatocellular carcinoma (HCC), especially in the abnormality of hepatic IGF-I receptor (IGF-IR) or IGF-II expression as a key molecule in hepatocarcinogenesis.
|
30360707 |
2019 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
IGF2 mRNA upregulation was observed in 9.4% of HCC and was not associated with higher INSRA:INSRB ratios.
|
30849481 |
2019 |
Russell-Silver syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Functional experiments were then used to link these genes into a regulatory pathway.ResultsWe report the first mutations of the PLAG1 gene in humans, as well as new mutations in HMGA2 and IGF2 in six sporadic and/or familial cases of SRS.
|
28796236 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that sodium ascorbate blocked HCC-induced activation of sulfatase-2 leading to restoration of HSPGs receptors associated with reduction in IGF-2 and glypican-3.
|
29669302 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genome wide expression profiling of CTCs using this approach demonstrates CTC heterogeneity and helps detect known oncogenic drivers in HCC such as IGF2.
|
30068984 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The LINC01138 locus is frequently amplified in HCC; the LINC01138 transcript is stabilized by insulin like growth factor-2 mRNA-binding proteins 1/3 (IGF2BP1/IGF2BP3) and is associated with the malignant features and poor outcomes of HCC patients.
|
29679004 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In epidemiologic and clinicopathological studies on chronic liver disease (CLD), lowered serum levels, decreased tissue expression of IGF1, elevated production of IGF1R and variable IGF2 expression has been noted, from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage.
|
29702590 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, inhibition of the menin/MLL interaction via MI-2/3 reduced IGF2 expression, inhibited the IGF1R-AKT pathway, and significantly repressed HCC with robust expression of IGF2.
|
29413895 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma.
|
30733684 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings implicate the activation of STAT3 as one pathway that may mediate resistance to IGF-II-targeted therapy in HCC.
|
29933129 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The effects of IGF-II on cell proliferation, cell cycle, apoptosis, cell migration, and invasion in HCC Huh7 cells were investigated in the study.
|
29970663 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
At immunohistochemistry (group C), the HCC with loss of cytoplasmic IGF2 expression showed a down-regulation of miR-483-3p (fold increase 0.57).
|
29707155 |
2018 |
Russell-Silver syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified, through whole-exome sequencing, a de novo IGF2 indel mutation leading to frameshift (NM_000612.5:c.110_117delinsAGGTAA, p.(Leu37Glnfs*31)) in a patient with Silver-Russell syndrome, ectrodactyly, undermasculinized genitalia, developmental delay, and placental hypoplasia.
|
28489339 |
2017 |
Russell-Silver syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our study provides further evidence that IGF2 mutation may be another mechanism of SRS, and we consider that IGF2 should be included in a disease specific gene panel in case it is designed for SRS routine diagnostics.
|
28848601 |
2017 |
Russell-Silver syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, no paternal deletions of ICR1 have ever been associated with hypomethylation of the IGF2/H19 domain in SRS.
|
27701793 |
2017 |
Russell-Silver syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we assess the value of IGF-2 in relation to SRS.
|
28675902 |
2017 |
Russell-Silver syndrome
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A further 2 patients had hypomethylation in the H19/IGF2 region or mUPD7 consistent with Silver-Russell Syndrome (total with genetic diagnosis 51/107, 48% or 41/97, 42% probands).
|
28870985 |
2017 |
Russell-Silver syndrome
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study shows that paternal IGF2/H19 domain triplication results in BWS, gives additional support to the hypothesis that the maternal amplification of IGF2/H19 domain may lead to the manifestation of SRS and underlines difficulties of genetic counseling in patients with CNVs involving the 11p15.5 region.
|
27612309 |
2017 |